Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses

Mitchell, Paul; Thatcher, Nick; Socinski, Mark A.; Wasilewska-Teśluk, Ewa; Horwood, Keith; Szczęsna, Aleksandra; Martín, Claudio; Ragulin, Yu. A.; Zukin, Mauro; Helwig, Christoph; Falk, M.; Butts, Charles; Shepherd, Frances A.

doi:10.1093/annonc/mdv104

Cited by 86 publications

(58 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A total of 7 studies were conducted in Western countries, including the UK (17,26,34), USA (28), Spain (20) and Italy (22,34), 1 study was performed in Turkey (23), and 10 studies were performed in East Asian countries, including Japan (18,19,31,32), Korea (21,25) and China (24,27,30,33). The study published by Mitchell et al (29) included patient data from 33 countries. The included studies evaluated 16 populations of patients with NSCLC (17-24,26-29,31-34) and 2 populations of patients with SCLC (25,30).…”

Section: Resultsmentioning

confidence: 99%

“…The included studies evaluated 16 populations of patients with NSCLC (17-24,26-29,31-34) and 2 populations of patients with SCLC (25,30). The 2 studies on SCLC reported tumor staging information as limited and extensive disease, so only the staging information from the studies regarding NSCLC were considered Only 1 study by Sarraf et al (17) evaluated all tumor stages, 8 studies evaluated early-stage tumors (23,(26)(27)(28)(29)(31)(32)(33), and 6 studies evaluated late-stage tumors (18,(20)(21)(22)24,34). The study by Tomita et al (19) evaluated stages IA/III/IV.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Value of neutrophil-to-lymphocyte ratio for predicting lung cancer prognosis: A meta-analysis of 7,219 patients

Liu

Cui

2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Current evidence suggests that the neutrophil-to-lymphocyte ratio (NLR) may be a biomarker for poor prognosis in lung cancer, although this association remains controversial. Therefore, a meta-analysis was performed to evaluate the association between NLR and lung cancer outcome. A systematic literature search was performed through the PubMed, Embase and Cochrane Library databases (until July 30, 2016), to identify studies evaluating the association between NLR and overall survival (OS) and/or progression-free survival (PFS) among patients with lung cancer. Based on the results of this search, data from 18 studies involving 7,219 patients with lung cancer were evaluated. The pooled hazard ratio (HR) suggested that elevated pretreatment NLR predicted poor OS [HR=1.46, 95% confidence interval (CI): 1.30-1.64] and poor PFS (HR=1.42, 95% CI: 1.15-1.75) among patients with lung cancer. Subgroup analysis revealed that the prognostic value of NLR for predicting poor OS increased among patients who underwent surgery (HR=1.50, 95% CI: 1.21-1.84) or patients with early-stage disease (HR=1.64, 95% CI: 1.37-1.97). An NLR cut-off value of ≥4 significantly predicted poor OS (HR=1.56, 95% CI: 1.31-1.85) and PFS (HR=1.54, 95% CI: 1.13-1.82), particularly in the cases of small-cell lung cancer. Thus, the results of the present meta-analysis suggested that an elevated pretreatment NLR (e.g., ≥4) may be considered as a biomarker for poor prognosis in patients with lung cancer.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Value of neutrophil-to-lymphocyte ratio for predicting lung cancer prognosis: A meta-analysis of 7,219 patients

Liu

Cui

2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…NCT00409188, a Phase III study testing tecemotide in combination with single low-dose cyclophosphamide in subjects with NSCLC has been completed. Primary endpoint was not met, but notable survival benefits were achieved in patients treated with concurrent chemoradiotherapy, 257 NCT01507103, a Phase II study testing the therapeutic profile of tecemotide combined with cyclophosphamide or cyclophosphamide plus chemoradiation in subjects with rectal cancer, has been completed. No difference in incidence and severity of adverse events were noted.…”

Section: Ongoing Clinical Trialsmentioning

confidence: 99%

Trial watch: Peptide-based vaccines in anticancer therapy

et al. 2018

View full text Add to dashboard Cite

Peptide-based anticancer vaccination aims at stimulating an immune response against one or multiple tumor-associated antigens (TAAs) following immunization with purified, recombinant or synthetically engineered epitopes. Despite high expectations, the peptide-based vaccines that have been explored in the clinic so far had limited therapeutic activity, largely due to cancer cell-intrinsic alterations that minimize antigenicity and/or changes in the tumor microenvironment that foster immunosuppression. Several strategies have been developed to overcome such limitations, including the use of immunostimulatory adjuvants, the co-treatment with cytotoxic anticancer therapies that enable the coordinated release of damage-associated molecular patterns, and the concomitant blockade of immune checkpoints. Personalized peptide-based vaccines are also being explored for therapeutic activity in the clinic. Here, we review recent preclinical and clinical progress in the use of peptide-based vaccines as anticancer therapeutics.Abbreviations: CMP: carbohydrate-mimetic peptide; CMV: cytomegalovirus; DC: dendritic cell; FDA: Food and Drug Administration; HPV: human papillomavirus; MDS: myelodysplastic syndrome; MHP: melanoma helper vaccine; NSCLC: non-small cell lung carcinoma; ODD: orphan drug designation; PPV: personalized peptide vaccination; SLP: synthetic long peptide; TAA: tumor-associated antigen; TNA: tumor neoantigen

show abstract

“…The authors justify this approach as statistically superior to analysis using standard thresholds (NLR: ≥3 and ≥5) by concluding that all other reports are biased in some way. However, there are also reports of NLR having prognostic value in prospectively collected data from clinical trials using standard thresholds, such as a NLR≥3(9-11) or ≥5 (12,13).…”

Section: Ross Dolan Donald Mcmillanmentioning

confidence: 99%

Neutrophil‐to‐lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710

Dolan

McMillan

2017

Cancer

View full text Add to dashboard Cite

Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses

Abstract: NCT00409188.

Cited by 86 publications

References 17 publications

Value of neutrophil-to-lymphocyte ratio for predicting lung cancer prognosis: A meta-analysis of 7,219 patients

Value of neutrophil-to-lymphocyte ratio for predicting lung cancer prognosis: A meta-analysis of 7,219 patients

Trial watch: Peptide-based vaccines in anticancer therapy

Neutrophil‐to‐lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710

Contact Info

Product

Resources

About